Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1875 2
1877 3
1880 2
1887 1
1893 1
1896 1
1900 1
1908 4
1909 5
1911 3
1912 1
1916 1
1922 1
1923 1
1925 2
1929 1
1946 2
1947 3
1948 3
1949 2
1950 1
1953 2
1954 1
1955 2
1956 1
1957 1
1958 3
1959 1
1960 4
1961 4
1962 6
1963 13
1964 6
1965 6
1966 13
1967 7
1968 11
1969 12
1970 17
1971 12
1972 15
1973 27
1974 23
1975 30
1976 22
1977 28
1978 25
1979 54
1980 47
1981 38
1982 23
1983 35
1984 33
1985 34
1986 36
1987 34
1988 40
1989 36
1990 39
1991 46
1992 43
1993 47
1994 43
1995 39
1996 32
1997 37
1998 25
1999 30
2000 34
2001 43
2002 34
2003 35
2004 42
2005 60
2006 49
2007 74
2008 57
2009 70
2010 86
2011 89
2012 92
2013 88
2014 98
2015 103
2016 104
2017 108
2018 127
2019 122
2020 144
2021 134
2022 144
2023 104
2024 40

Text availability

Article attribute

Article type

Publication date

Search Results

2,970 results

Results by year

Filters applied: . Clear all
Page 1
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, Tombal B, Gillessen S; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Parker C, et al. Ann Oncol. 2020 Sep;31(9):1119-1134. doi: 10.1016/j.annonc.2020.06.011. Epub 2020 Jun 25. Ann Oncol. 2020. PMID: 32593798 Free article. No abstract available.
Click Chemistry in Proteomic Investigations.
Parker CG, Pratt MR. Parker CG, et al. Cell. 2020 Feb 20;180(4):605-632. doi: 10.1016/j.cell.2020.01.025. Epub 2020 Feb 13. Cell. 2020. PMID: 32059777 Free PMC article. Review.
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, Gillessen S, Cook A, Brawley C, Amos CL, Atako N, Pugh C, Buckner M, Chowdhury S, Malik Z, Russell JM, Gilson C, Rush H, Bowen J, Lydon A, Pedley I, O'Sullivan JM, Birtle A, Gale J, Srihari N, Thomas C, Tanguay J, Wagstaff J, Das P, Gray E, Alzoueb M, Parikh O, Robinson A, Syndikus I, Wylie J, Zarkar A, Thalmann G, de Bono JS, Dearnaley DP, Mason MD, Gilbert D, Langley RE, Millman R, Matheson D, Sydes MR, Brown LC, Parmar MKB, James ND; Systemic Therapy in Advancing or Metastatic Prostate cancer: Evaluation of Drug Efficacy (STAMPEDE) investigators. Attard G, et al. Among authors: parker cc. Lancet. 2022 Jan 29;399(10323):447-460. doi: 10.1016/S0140-6736(21)02437-5. Epub 2021 Dec 23. Lancet. 2022. PMID: 34953525 Free PMC article.
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt DE, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Omlin A. Gillessen S, et al. Among authors: parker c. Eur Urol. 2022 Jul;82(1):115-141. doi: 10.1016/j.eururo.2022.04.002. Epub 2022 Apr 18. Eur Urol. 2022. PMID: 35450732 Free article.
Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical Trial.
Palma DA, Prisman E, Berthelet E, Tran E, Hamilton S, Wu J, Eskander A, Higgins K, Karam I, Poon I, Husain Z, Enepekides D, Hier M, Sultanem K, Richardson K, Mlynarek A, Johnson-Obaseki S, Odell M, Bayley A, Dowthwaite S, Jackson JE, Dzienis M, O'Neil J, Chandarana S, Banerjee R, Hart R, Chung J, Tenenholtz T, Krishnan S, Le H, Yoo J, Mendez A, Winquist E, Kuruvilla S, Stewart P, Warner A, Mitchell S, Chen J, Parker C, Wehrli B, Kwan K, Theurer J, Sathya J, Hammond JA, Read N, Venkatesan V, MacNeil SD, Fung K, Nichols AC. Palma DA, et al. Among authors: parker c. JAMA Oncol. 2022 Jun 1;8(6):1-7. doi: 10.1001/jamaoncol.2022.0615. JAMA Oncol. 2022. PMID: 35482348 Free PMC article. Clinical Trial.
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Ali A, Hoyle A, Haran ÁM, Brawley CD, Cook A, Amos C, Calvert J, Douis H, Mason MD, Dearnaley D, Attard G, Gillessen S, Parmar MKB, Parker CC, Sydes MR, James ND, Clarke NW. Ali A, et al. Among authors: parker cc. JAMA Oncol. 2021 Apr 1;7(4):555-563. doi: 10.1001/jamaoncol.2020.7857. JAMA Oncol. 2021. PMID: 33599706 Free PMC article. Clinical Trial.
Chemoproteomic-enabled phenotypic screening.
Conway LP, Li W, Parker CG. Conway LP, et al. Among authors: parker cg. Cell Chem Biol. 2021 Mar 18;28(3):371-393. doi: 10.1016/j.chembiol.2021.01.012. Epub 2021 Feb 11. Cell Chem Biol. 2021. PMID: 33577749 Free article. Review.
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, Chien AJ, Forero-Torres A, Ellis E, Han H, Clark A, Albain K, Boughey JC, Jaskowiak NT, Elias A, Isaacs C, Kemmer K, Helsten T, Majure M, Stringer-Reasor E, Parker C, Lee MC, Haddad T, Cohen RN, Asare S, Wilson A, Hirst GL, Singhrao R, Steeg K, Asare A, Matthews JB, Berry S, Sanil A, Schwab R, Symmans WF, van 't Veer L, Yee D, DeMichele A, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Berry DA, Esserman LJ. Nanda R, et al. Among authors: parker c. JAMA Oncol. 2020 May 1;6(5):676-684. doi: 10.1001/jamaoncol.2019.6650. JAMA Oncol. 2020. PMID: 32053137 Free PMC article. Clinical Trial.
2,970 results